Skip to main content
Erschienen in: Archives of Dermatological Research 6/2016

20.05.2016 | Original Paper

Quality of psoriasis care in Germany: results of the national health care study “PsoHealth3”

verfasst von: Anna Langenbruch, Marc Alexander Radtke, Arnd Jacobi, Sandra Purwins, Kristina Haack, Kristian Reich, Klaus Stroemer, Ulrich Mrowietz, Matthias Augustin

Erschienen in: Archives of Dermatological Research | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Two national surveys conducted in 2005 and 2007 indicated deficits in psoriasis care and induced the composition of the ‘‘National Goals for Health Care in Psoriasis 2010–2015’’. The aim of this work was to (1) evaluate the quality of care for patients with psoriasis in Germany, (2) compare this with prior psoriasis studies PsoHealth1 (2005) and PsoHealth2 (2007), and (3) review the implementation of national treatment goals. By means of a cross sectional study the following indicators of health care quality were collected: psoriasis severity (Psoriasis Area Severity Index (PASI) and proportion of PASI >20), quality of life (Dermatology Life Quality Index (DLQI) were corporated: proportion of DLQI >10), previous systemic treatment, inpatient treatment, and days absent from work due to psoriasis. Between January 2013 and March 2014, 1265 patients from 82 dermatological centres were included (mean age of 52 years). 9.2 % had a PASI >20 (2007: 11.6 %; 2005: 17.8 %). 21.3 % reported strong quality of life restrictions (DLQI >10) (2007: 28.2 %; 2005: 34.0 %). 59.5 % had received a systemic treatment at least once within the last 5 years (2007: 47.3 %; 2005: 32.9 %). 20.1 % were treated inpatient within the last 5 years (2007: 20.1 %; 2005: 26.9 %). The current data indicate a better health care situation for psoriasis in Germany. The implementation of the S3-Guideline and the ‘‘National Goals for Health Care in Psoriasis 2010–2015’’ could have been contributing factors.
Literatur
1.
Zurück zum Zitat Augustin M (2008) PsoNet—more health care quality through regional psoriasis networks. J Dtsch Dermatol Ges 6(4):263–264CrossRefPubMed Augustin M (2008) PsoNet—more health care quality through regional psoriasis networks. J Dtsch Dermatol Ges 6(4):263–264CrossRefPubMed
2.
Zurück zum Zitat Augustin M, Alvaro-Gracia JM, Bagot M et al (2012) A framework for improving the quality of care for people with psoriasis. J Eur Acad Dermatol Venereol 26(Suppl 4):1–16CrossRefPubMed Augustin M, Alvaro-Gracia JM, Bagot M et al (2012) A framework for improving the quality of care for people with psoriasis. J Eur Acad Dermatol Venereol 26(Suppl 4):1–16CrossRefPubMed
3.
Zurück zum Zitat Augustin M, Chapnik J, Gupta S et al (2011) Psoriasis causes high costs, reduces productivity at work and quality of life. Akt Dermatol 37(10):353–359CrossRef Augustin M, Chapnik J, Gupta S et al (2011) Psoriasis causes high costs, reduces productivity at work and quality of life. Akt Dermatol 37(10):353–359CrossRef
4.
Zurück zum Zitat Augustin M, Glaeske G, Radtke MA et al (2010) Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 162(3):633–636CrossRefPubMed Augustin M, Glaeske G, Radtke MA et al (2010) Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 162(3):633–636CrossRefPubMed
5.
Zurück zum Zitat Augustin M, Glaeske G, Schäfer I et al (2012) Processes of Psoriasis Health Care in Germany—long-term analysis of data from the statutory health insurances. J Dtsch Dermatol Ges 10(9):648–655PubMed Augustin M, Glaeske G, Schäfer I et al (2012) Processes of Psoriasis Health Care in Germany—long-term analysis of data from the statutory health insurances. J Dtsch Dermatol Ges 10(9):648–655PubMed
6.
Zurück zum Zitat Augustin M, Herberger K, Hintzen S et al (2011) Prevalence of skin lesions and need for treatment in a cohort of 90,880 workers. Br J Dermatol 165(4):865–873CrossRefPubMed Augustin M, Herberger K, Hintzen S et al (2011) Prevalence of skin lesions and need for treatment in a cohort of 90,880 workers. Br J Dermatol 165(4):865–873CrossRefPubMed
7.
Zurück zum Zitat Augustin M, Krüger K, Radtke MA et al (2008) Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology 216(4):366–372CrossRefPubMed Augustin M, Krüger K, Radtke MA et al (2008) Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology 216(4):366–372CrossRefPubMed
8.
Zurück zum Zitat Augustin M, Radtke MA, Zschocke I et al (2009) The patient benefit index: a novel approach in patient-defined outcomes measurement for skin diseases. Arch Dermatol Res 301(8):561–571CrossRefPubMed Augustin M, Radtke MA, Zschocke I et al (2009) The patient benefit index: a novel approach in patient-defined outcomes measurement for skin diseases. Arch Dermatol Res 301(8):561–571CrossRefPubMed
9.
Zurück zum Zitat Augustin M, Reich K, Blome C et al (2010) Nail psoriasis in Germany: epidemiology and burden of disease. Br J Dermatol 163(3):580–585CrossRefPubMed Augustin M, Reich K, Blome C et al (2010) Nail psoriasis in Germany: epidemiology and burden of disease. Br J Dermatol 163(3):580–585CrossRefPubMed
10.
Zurück zum Zitat Augustin M, Reich K, Glaeske G et al (2013) Drug supply for children with psoriasis in Germany. J Dtsch Dermatol Ges 11(8):751–755PubMed Augustin M, Reich K, Glaeske G et al (2013) Drug supply for children with psoriasis in Germany. J Dtsch Dermatol Ges 11(8):751–755PubMed
11.
Zurück zum Zitat Augustin M, Reich K, Reich C et al (2008) Quality of psoriasis care in Germany—results of the national study PsoHealth 2007. J Dtsch Dermatol Ges 6(8):640–645CrossRefPubMed Augustin M, Reich K, Reich C et al (2008) Quality of psoriasis care in Germany—results of the national study PsoHealth 2007. J Dtsch Dermatol Ges 6(8):640–645CrossRefPubMed
12.
Zurück zum Zitat Augustin M, Schäfer I, Reich K et al (2011) Systemic treatment with corticosteroids in psoriasis-health care provision far beyond the S3-guidelines. J Dtsch Dermatol Ges 9(10):833–838PubMed Augustin M, Schäfer I, Reich K et al (2011) Systemic treatment with corticosteroids in psoriasis-health care provision far beyond the S3-guidelines. J Dtsch Dermatol Ges 9(10):833–838PubMed
13.
Zurück zum Zitat Augustin M, Zschocke I, Seidenglanz K et al (2000) Validation and clinical results of the FLQA-d, a quality of life questionnaire for patients with chronic skin diseases. Dermatol Psychosom 1(1):12–17CrossRef Augustin M, Zschocke I, Seidenglanz K et al (2000) Validation and clinical results of the FLQA-d, a quality of life questionnaire for patients with chronic skin diseases. Dermatol Psychosom 1(1):12–17CrossRef
14.
Zurück zum Zitat Blome C, Simianer S, Purwins S et al (2010) Time needed for treatment is the major predictor of quality of life in psoriasis. Dermatology 221(2):154–159CrossRefPubMed Blome C, Simianer S, Purwins S et al (2010) Time needed for treatment is the major predictor of quality of life in psoriasis. Dermatology 221(2):154–159CrossRefPubMed
15.
Zurück zum Zitat Deutsche Dermatologische Gesellschaft (DDG), Berufsverband der Deutschen Dermatologen (BVDD) (2015) Regionale Psoriasisnetze in Deutschland. http://www.psonet.de. Accessed 6 Jan 2015 Deutsche Dermatologische Gesellschaft (DDG), Berufsverband der Deutschen Dermatologen (BVDD) (2015) Regionale Psoriasisnetze in Deutschland. http://​www.​psonet.​de. Accessed 6 Jan 2015
16.
Zurück zum Zitat Deutsche Dermatologische Gesellschaft (DDG), Berufsverband der Deutschen Dermatologen (BVDD), Competenzzentrum Versorgungsforschung in der Dermatologie (CVderm) (2014) Psoriasis Nationale Versorgungsziele. http://www.versorgungsziele.de/. Accessed 19 Dec 2014 Deutsche Dermatologische Gesellschaft (DDG), Berufsverband der Deutschen Dermatologen (BVDD), Competenzzentrum Versorgungsforschung in der Dermatologie (CVderm) (2014) Psoriasis Nationale Versorgungsziele. http://​www.​versorgungsziele​.​de/​. Accessed 19 Dec 2014
17.
Zurück zum Zitat Dubertret L, Mrowietz U, Ranki A et al (2006) European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 155(4):729–736CrossRefPubMed Dubertret L, Mrowietz U, Ranki A et al (2006) European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 155(4):729–736CrossRefPubMed
18.
Zurück zum Zitat Feldman SR, Krueger GG (2005) Psoriasis assessment tools in clinical trials. Ann Rheum Dis 64(Suppl 2):ii65–ii68PubMedPubMedCentral Feldman SR, Krueger GG (2005) Psoriasis assessment tools in clinical trials. Ann Rheum Dis 64(Suppl 2):ii65–ii68PubMedPubMedCentral
19.
Zurück zum Zitat Feuerhahn J, Blome C, Radtke M et al (2012) Validation of the patient benefit index for the assessment of patient-relevant benefit in the treatment of psoriasis. Arch Dermatol Res 304(6):433–441CrossRefPubMed Feuerhahn J, Blome C, Radtke M et al (2012) Validation of the patient benefit index for the assessment of patient-relevant benefit in the treatment of psoriasis. Arch Dermatol Res 304(6):433–441CrossRefPubMed
20.
Zurück zum Zitat Finlay AY, Khan GK (1994) Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol 19(3):210–216CrossRefPubMed Finlay AY, Khan GK (1994) Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol 19(3):210–216CrossRefPubMed
21.
Zurück zum Zitat Kimball AB, Gieler U, Linder D et al (2010) Psoriasis: is the impairment to a patient’s life cumulative? J Eur Acad Dermatol Venereol 24(9):989–1004PubMed Kimball AB, Gieler U, Linder D et al (2010) Psoriasis: is the impairment to a patient’s life cumulative? J Eur Acad Dermatol Venereol 24(9):989–1004PubMed
22.
Zurück zum Zitat Krueger G, Koo J, Lebwohl M et al (2001) The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 137(3):280–284PubMed Krueger G, Koo J, Lebwohl M et al (2001) The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 137(3):280–284PubMed
23.
Zurück zum Zitat Nast A, Kopp IB, Augustin M et al (2006) S3-guidelines for the treatment of psoriasis vulgaris. J Dtsch Dermatol Ges 4(Suppl2):S1–126CrossRefPubMed Nast A, Kopp IB, Augustin M et al (2006) S3-guidelines for the treatment of psoriasis vulgaris. J Dtsch Dermatol Ges 4(Suppl2):S1–126CrossRefPubMed
24.
Zurück zum Zitat Radtke MA, Reich K, Blome C et al (2009) Evaluation of quality of care and guideline-compliant treatment in psoriasis. Development of a new system of quality indicators. Dermatology 219(1):54–58CrossRefPubMed Radtke MA, Reich K, Blome C et al (2009) Evaluation of quality of care and guideline-compliant treatment in psoriasis. Development of a new system of quality indicators. Dermatology 219(1):54–58CrossRefPubMed
25.
Zurück zum Zitat Radtke MA, Reich K, Blome C et al (2009) Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey. J Eur Acad Dermatol Venereol 23(6):683–691CrossRefPubMed Radtke MA, Reich K, Blome C et al (2009) Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey. J Eur Acad Dermatol Venereol 23(6):683–691CrossRefPubMed
26.
Zurück zum Zitat Reich K, Krüger K, Mössner R et al (2009) Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol 160(5):1040–1047CrossRefPubMed Reich K, Krüger K, Mössner R et al (2009) Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol 160(5):1040–1047CrossRefPubMed
27.
Zurück zum Zitat Schmid-Ott G, Künsebeck H, Jäger B et al (2005) Significance of the stigmatization experience of psoriasis patients: a 1-year follow-up of the illness and its psychosocial consequences in men and women. Acta Derm Venereol 85(1):27–32CrossRefPubMed Schmid-Ott G, Künsebeck H, Jäger B et al (2005) Significance of the stigmatization experience of psoriasis patients: a 1-year follow-up of the illness and its psychosocial consequences in men and women. Acta Derm Venereol 85(1):27–32CrossRefPubMed
28.
Zurück zum Zitat Schöffski O, Augustin M, Prinz J et al (2007) Costs and quality of life in patients with moderate-to-severe plaque-type psoriasis in Germany: a multi-center study. J Dtsch Dermatol Ges 5(3):209–218CrossRefPubMed Schöffski O, Augustin M, Prinz J et al (2007) Costs and quality of life in patients with moderate-to-severe plaque-type psoriasis in Germany: a multi-center study. J Dtsch Dermatol Ges 5(3):209–218CrossRefPubMed
29.
Zurück zum Zitat Sohn S, Schoeffski O, Prinz J et al (2006) Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study. Dermatology 212(2):137–144CrossRefPubMed Sohn S, Schoeffski O, Prinz J et al (2006) Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study. Dermatology 212(2):137–144CrossRefPubMed
30.
Zurück zum Zitat Taylor WJ (2012) Impact of psoriatic arthritis on the patient: through the lens of the WHO International Classification of Functioning, Health, and Disability. Curr Rheumatol Rep 14(4):369–374CrossRefPubMed Taylor WJ (2012) Impact of psoriatic arthritis on the patient: through the lens of the WHO International Classification of Functioning, Health, and Disability. Curr Rheumatol Rep 14(4):369–374CrossRefPubMed
31.
Zurück zum Zitat Zachariae H, Zachariae R, Blomqvist K et al (2002) Quality of life and prevalence of arthritis reported by 5,795 Members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study. Acta Derm Venereol 82(2):108–113CrossRefPubMed Zachariae H, Zachariae R, Blomqvist K et al (2002) Quality of life and prevalence of arthritis reported by 5,795 Members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study. Acta Derm Venereol 82(2):108–113CrossRefPubMed
Metadaten
Titel
Quality of psoriasis care in Germany: results of the national health care study “PsoHealth3”
verfasst von
Anna Langenbruch
Marc Alexander Radtke
Arnd Jacobi
Sandra Purwins
Kristina Haack
Kristian Reich
Klaus Stroemer
Ulrich Mrowietz
Matthias Augustin
Publikationsdatum
20.05.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Archives of Dermatological Research / Ausgabe 6/2016
Print ISSN: 0340-3696
Elektronische ISSN: 1432-069X
DOI
https://doi.org/10.1007/s00403-016-1651-x

Weitere Artikel der Ausgabe 6/2016

Archives of Dermatological Research 6/2016 Zur Ausgabe

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.